Can existing drugs be reimagined to fight cancer? This Frontiers in Oncology article explores the growing field of drug repurposing, where already-approved medications are investigated for new therapeutic uses. The study examines how researchers navigate regulatory challenges, funding obstacles, and intellectual property issues to bring these “new” cancer treatments to market. With faster approval timelines and reduced costs compared to developing entirely new drugs, repurposing could be a game-changer leading to lower drug prices. EVAs use case 2 is therefore dedicated to exploring how to speed up the selection of repurposing-targets.
